TY - JOUR
T1 - ITRAQ-based proteomics reveals novel biomarkers of osteoarthritis
AU - Ikeda, Daiki
AU - Ageta, Hiroshi
AU - Tsuchida, Kunihiro
AU - Yamada, Harumoto
N1 - Funding Information:
This work was partially supported by Supported Program for the Strategic Research Foundation at Private Universities (MEXT) and an Intramural Research Grant (23-5) for Neurological and Psychiatric Disorders of NCNP. All authors declare that there is no conflict of interest.
PY - 2013/11
Y1 - 2013/11
N2 - Objective: We performed comprehensive proteomic analyses of articular cartilage by using the isobaric tags for relative and absolute quantitation (iTRAQ) method, and searched for candidate biomarkers for osteoarthritis (OA). Methods: Articular cartilage was collected from patients with OA or femoral neck fracture for the control group. Molecular variations were detected by the iTRAQ method, and quantitative analyses were performed by western blot. Results: Using the iTRAQ method, we identified 76 proteins with different expression levels in OA patients and the control group. Among these proteins, we selected LECT2 (leukocyte cell-derived chemotaxin-2), BAALC (brain and acute leukemia, cytoplasmic), and PRDX6 (peroxiredoxin-6), which had not been reported as biomarkers for OA. Conclusions: Use of these proteins in combination with conventional OA biomarkers may better reflect the grade and prognosis of OA.
AB - Objective: We performed comprehensive proteomic analyses of articular cartilage by using the isobaric tags for relative and absolute quantitation (iTRAQ) method, and searched for candidate biomarkers for osteoarthritis (OA). Methods: Articular cartilage was collected from patients with OA or femoral neck fracture for the control group. Molecular variations were detected by the iTRAQ method, and quantitative analyses were performed by western blot. Results: Using the iTRAQ method, we identified 76 proteins with different expression levels in OA patients and the control group. Among these proteins, we selected LECT2 (leukocyte cell-derived chemotaxin-2), BAALC (brain and acute leukemia, cytoplasmic), and PRDX6 (peroxiredoxin-6), which had not been reported as biomarkers for OA. Conclusions: Use of these proteins in combination with conventional OA biomarkers may better reflect the grade and prognosis of OA.
UR - http://www.scopus.com/inward/record.url?scp=84888864944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888864944&partnerID=8YFLogxK
U2 - 10.3109/1354750X.2013.810667
DO - 10.3109/1354750X.2013.810667
M3 - Article
C2 - 23937207
AN - SCOPUS:84888864944
SN - 1354-750X
VL - 18
SP - 565
EP - 572
JO - Biomarkers
JF - Biomarkers
IS - 7
ER -